. FACS analysis can be used to reliably isolate CA125 positive versus negative cells from high grade serous cancers. (a) Quantitative-PCR measurement of CA125 transcripts confirmed reports that CA125 is highly expressed in Ovcar-3 but not Skov3 cells. Results are mean ± SD, n=3. To validate detection of CA125 antigen, mixed populations of Ovcar-3 and Skov-3 cells were stained with commercially available OC125 antibody, isolated using FACS and cytospun. Appropriate signal was detected by fluorescent microscopy in sorted cell populations. Probing these samples with a second anti-CA125 antibody directed against a different epitope of the antigen confirmed the accuracy of this isolation. (b) Human HGSCs were mechanically and enzymatically dissociated to single cells and analyzed by FACS. After elimination of hematopoietic, endothelial and red blood cells using the lineage markers CD31, CD45 and CD235a the proportions of CA125 positive and negative cells were determined. Post-sort purity analysis showed accurate separation of these cellular subpopulations (n=3) confirmed by western blot. Scale bars equal 5 mm for tumor and 100 µm for cells. Limiting dilution assays confirmed CA125 negative cells were the cells that initiate serous tumors. Gross tumors generated from 5 other independent chemo-naive human HGSCs used in this experiment are shown. Scale bars equal 5 mm. (b) In vivo lineage tracing experiments on a second independent specimen confirmed that the CA125 negative HGSC subpopulation could differentiate into both CA125 positive and CA125 negative cells, while progeny of CA125 positive cells were predominantly CA125 positive. Scale bars equal 5 mm for gross tumors and 50 µm for stained cells. (c) In the two ascites samples that exhibited growth from both CA125 subpopulations, tumors generated from the CA125 negative HGSC cells expressed CA125 on some but not all cells while tumors generated from CA125 positive cells uniformly expressed CA125. Scale bars equal 50 µm. Supplementary Fig. 3 10 5 10 4 10 3 10 2 10 5 10 4 10 3 10 2 10 5 10 4 10 3 10 2 # cells injected 2/2 0/3 0/3 0/3 0/2 0/3 0/3 0/2 0/3 0/3 0/3 0/3 Tumor take frequency hHGSC 5 2/2 3/3 3/3 2/3 1/2 0/3 0/3 3/3 2/3 0/3 0/3 0/3 Tumor take frequency hHGSC 4 1/2 0/3 0/3 0/3 0/2 0/3 0/3 0/2 0/3 0/3 0/3 0/3 Tumor take frequency hHGSC 6 2/2 3/3 2/3 0/3 0/2 0/3 0/3 2/2 0/3 0/3 0/3 0/3 Tumor take frequency hHGSC 7 3/3 3/3 2/3 1/3 1/3 0/3 0/3 3/3 1/3 0/3 0/3 0/3 Tumor take frequency hHGSC 3 a b CA125   CA125   CA125  TP53  H&E  CA125  TP53  H&E   CA125  TP53  H&E  CA125  TP53  H&E   CA125  TP53  H&E  CA125  TP53  H&E   CA125  TP53  H&E  CA125  TP53 Figure 6 . Characterization of the low passage, patient derived HGSC cell lines S1-, S3-and S5-GODL. (a) Based on FACS analysis, subsets of low-passage patient derived HGSC cell lines (S1-, S3-and S5-GODL) are CA125 negative in comparable proportion to the parent tumor. (b) Only the CA125 negative subpopulation of these cell lines efficiently gave rise to tumors (n=3 replicates). Genomic copy number variation analysis revealed conserved amplifications and deletions between the cell lines and parent tumors, while clustering analysis confirms similarity between transcript expression patterns. Elevated expression of cIAP proteins was detected in the CA125 negative subpopulation of all lines by western blot. (c) Calculation of the correlation between cell lines and parent tumors indicated that each cell line closely resembled their parent HGSC (r 2 = 0.841 for S1-GODL, 0.996 for S3 GODL and 0.908 for S5-GODL). R 2 calculated using R function of hclust(). 
S5-GODL
Parent HGSC for S1 S1-GODL (a) FACS analysis demonstrated that in S1-GODL, S3-GODL and S5-GODL cell lines, all cells including the CA125 negative population, could be eliminated with birinapant and carboplatin cotreatment in vitro. CA125 negative tumor cells were resistant to Carboplatin alone. Birinapant as a single agent caused only partial cell death. Averaging this data as a plot of cell survival for S1,3&5-GODL cell lines demonstrated that only combined birinapant and carboplatin cotreatment resulted in complete tumor cell kill (n=3 replicates per sample). Birinapant mediated degradation of cIAP and apoptotic induced PARP cleavage is confirmed by western blot in S1,3&5-GODL treated cells. (b) To achieve selective knockdown of cIAP proteins, S1-GODL, S3-GODL, or S5-GODL cells were infected with lentivirus expressing short hairpin RNAs targeting cIAP1, cIAP2 , cIAP1&cIAP2 or a scrambled control. After elimination of uninfected cells by puromycin treatment, cells were treated in triplicates with either vehicle or carboplatin. Cell survival (determined by propidium iodide and annexin V negativity) and CA125 expression was quantified by FACS analysis. Graphs of cell survival for the bulk cells and the CA125 negative subpopulation is shown for each cell line. Results are mean ± SD, n=3. Knockdown of cIAP1 and cIAP2 together sensitized the CA125 negative cells to carboplatin treatment, resulting in complete cell death. Knockdown of neither cIAP alone could cause complete elimination of CA125 negative cells in response to carboplatin. Specific knockdown of cIAP proteins was verified by QPCR for cIAP1 and cIAP2 transcripts and western blot. Collectively, these results show sensitization of the CA125 negative HGSC cells is likely a direct result of cIAP degradation. 
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S3-GODL
S5-GODL S1-GODL bars equal 50 µm. (d) While obvious tumor was detected in all carboplatin treated xenografts, disease was detected in only 5 of 11 subcutaneous xenografts in the co-therapy arm one month after the cessation of therpy, and these foci were small compared to carboplatin treated tumors. Resurgence of CA125 positive cells was observed in carboplatin treated grafts after therapy was stopped. Scale bars equal 50 µm (e) Serial measurement of tumor volume demonstrates that in contrast to other treatment groups, xenografts treated with birinapant and carboplatin co-therapy do not increase in size following the cessation of treatment. Results are mean ± SEM, n=4 per group. (f) Full xenograft images are shown to demonstrate that when disease foci were detected in birinapant and carboplatin treated grafts released from therapy; these foci were very small compared to tumors in the carboplatin treated arm. Scale bars equal 500 µm Supplementary Figure 12 
